initi coverag crispr crsp market
outperform rate price target base compar compani
analysi one lead compani burgeon
field gene edit made far facil econom via
understand manipul exploit view
main focu crispr platform ex vivo crispr applic
hemoglobinopathi immuno-oncolog compani wholli own ex vivo
platform seek develop allogen car-t treatment
malign crsp partner mo
pt bayko develop ex vivo edit hematopoiet stem cell hsc
treatment sickl cell diseas scd beta-thalassemia -thal
differenti focu edit cell ex vivo deliveri
crispr compon larg solv crsp find amongst
leader race commerci first crispr-bas therapeut
submit clinic trial agreement cta addit
vertex collabor provid signific valid crsp technolog
crispr form casebia joint ventur bayer
develop vivo crispr treatment hemophilia provid
compani strong foundat develop vivo crispr-bas approach
futur crsp licens promis lipid nanoparticl lnp deliveri
technolog laboratori dr daniel anderson mit crsp also recent
sign collabor agreement curevac clinic grade mrna
lead team scientif advisor execut increas likelihood
long-term success crispr scientif founder wide
recogn made semin contribut understand crispr
biolog founder emmanuel charpenti ph max planck institut
infect biolog co-author landmark paper along jennif doudna
ph univers california berkeley programm dual-rna-
guid endonucleas adapt bacteri immun jinek et al scienc
establish dr charpenti co-inventor engin single-guid rna
crispr technolog foundat nearli crispr base medicin
kulkarni ph formerli partner mckinsey head research develop
toni ho formerli head oncolog innov astrazeneca cfo
michael tomsicek formerli cfo head immuno-oncolog
research jon terrett ph formerli vice presid oncolog discoveri
intellectu properti still bit unsettl barrier
success space observ crispr space may know
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
februari patent trial appeal board ptab rule current
appeal beyond scope report determin parti
think win believ parti ultim find way either oper
freeli pay royalti third parti also possibl cross-licens
arrang amongst parti involv given import field
scenario like take number year determin
reach view
crispr technolog rapidli emerg stand-alone therapeut class
crispr still infanc see improv technolog
advanc rapidli gene-edit technolog talen
zinc finger protein zfp come perform mani
function crispr technolog distinguish eas use low cost
multiplex capabl mani technolog hurdl still need overcom
confid crispr emerg lead therapeut develop
differenti strategi focus ex vivo platform crispr focu ex vivo
edit hsc scd -thal well edit car-t malign
maxim compani chanc clinic success opinion deliv
guid rna protein vivo remain signific challeng abil use crispr
modifi genom cell outsid bodi wide establish virtual
deliveri challeng edit compani need electropor approach
pioneer decad ago similarli crispr use virus deliv crispr
compon chimer antigen receptor -t cell
thu believ focus ex vivo approach maxim sharehold return near
term valid target car-t space two autolog car-t treatment
recent receiv fda approv treatment dlbcl compani decid
pursu develop allogen car-t direct believ allogen
car-t enabl scalabl off-the-shelf product compet costli difficult
manufactur autolog car-t significantli compani wholli own car-t platform given
econom gilead recent acquisit kite subsequ acquisit cell design lab
gilead kite believ strategi creat signific valu time
recent societi immunotherapi cancer confer novemb compani
present compel proof-of-concept data two addit allogen car-t candid first
target second target bcma treat hematologic/solid tumor multipl
myeloma addit abl expand car-t platform crispr also
work toward develop next gener enhanc car-t checkpoint inhibitor
knock use crispr
vy lead race bring crispr-bas medicin market thrust
compani effort ex vivo edit hsc car-t believ crispr
increas likelihood first compani commerci crispr-bas therapeut
inde compani file cta -thal anticip ind file
allogen car-t treat patient dlbcl believ compani
effort develop crispr-bas medicin bring market quickli benefit patient
sharehold crsp face competit edit hsc scd -thal compani
focus use crispr upregul fetal hemoglobin fh hsc ex vivo
similarli compani face competit effort use crispr develop allogen car-t
nevertheless use crispr remov gene express within cell
reintroduc patient mediat graft-versus-host diseas gvhd host-versus-graft diseas
believ crispr allogen car-t enabl compani develop potent
consist off-the-shelf product significantli reduc cost compar recent approv autolog
car-t view crsp rapidli supplant approv autolog competitor
domin car-t space model peak revenu billion
develop vivo platform compani focus near term ex vivo platform
work develop vivo edit approach sustain long-term growth collabor
dr daniel anderson mit crispr develop proprietari lnp technolog deliv
crispr liver lnp demonstr reduct serum protein use
total rna addit compani collabor curevac ag privat
provid mrna manufactur clinic develop given hurdl gmp manufactur
pose oligonucleotid compani past crispr take prudent measur
ensur vivo program remain track opinion
strong industri collabor valid potenti crispr crispr therapeut form
collabor bayer vertex valid potenti compani crispr technolog
platform view casebia joint ventur bayer own two
compani crsp receiv up-front payment crispr initi
public offer commit jv fund bayer co-develop crispr-bas
medicin hemophilia scid well investig high-reward diseas area
ophthalmolog cardiolog crsp receiv front billion potenti
mileston vertex plu royalti research fund collabor develop crispr-
base medicin cystic fibrosi hemoglobinopathi term collabor
hemoglobinopathi co-developed/co-commerci crsp lead commerci
parti
lead team scientif advisor execut increas likelihood long-term
formerli partner mckinsey head research develop toni ho formerli head
oncolog innov astrazeneca head immuno-oncolog research jon terrett ph
formerli vice presid oncolog discoveri cytomx season execut aim
advanc foundat basic research pioneer compani scientif founder dr
emmanuel charpenti co-author along jennif doudna ph univers california
berkeley landmark paper programm dual-rna-guid endonucleas adapt bacteri
immun jinek et al scienc dr charpenti co-inv engin single-guid rna
crispr technolog foundat nearli crispr base medicin
given earli stage compani candid pipelin note crispr
therapeut potenti pursu therapi address
technolog valuat deriv primarili compar valuat analysi view
crispr premier biotechnolog compani pursu genom
edit strategi shown figur list peer includ gene therapi compani
oligonucleotide-focus biotechnolog compani car-t compani current trade
mean market cap take ratio mean ev group peer crsp
ev multipli current crsp share price deriv compar valuat
price march
crispr inc crsp biotechnolog compani base zug switzerland
cambridg focus translat transform novel genom edit technolog known
human therapeut technolog util crsp develop
compani scientif founder dr emmanuel charpenti dr charpenti insight may pave
way treatment genetically-driven diseas precis correct molecular modif
crsp lead program edit car-t cell posit malign edit hsc
scd -thal emphas compani focu ex vivo gene edit approach
compani wholli own program includ develop crispr-bas medicin
posit malign hurler syndrom glycogen storag diseas ia gsdia
duschenn muscular dystrophi dmd crsp collabor vertex develop crispr base
medicin scd -thal cystic fibrosi cf establish casebia joint ventur
bayer bayn nc develop crispr base medicin hemophilia crsp vertex file cta
anticip ind
technolog like biotechnolog compani crispr subject rang risk
relat challeng associ drug discoveri develop addit crsp core
technolog larger space still rel immatur thu far crispr-bas
genome-edit therapeut reach clinic develop addit limit
number clinic trial involv genome-edit technolog product util genom
edit approv
intellectu properti crispr reli heavili patent right certain third parti
develop compani technolog includ technolog intellectu
properti claim current uncertain may reinterpret issuanc
could neg impact investor enthusiasm crsp share regent
univers california uc crsp appeal februari interfer decis
clinic drug develop inher riski enterpris crispr could
experi clinic trial failur one program clinic setback could larger
normal effect share investor may lose faith underli technolog addit
specif program issu neg outcom one compani clinic program
one competitor therapeut involv technolog
partner crispr therapeut form joint ventur vertex bayer chang
arrang could substanti neg impact compani share price
adequ resourc fund oper least month
view anticip crispr therapeut like seek addit equiti financ
form secondari offer order complet develop drug candid creat
dilut risk exist sharehold
crispr use crispr disrupt gene treatment hemoglobinopathi
dmd posit malign correct gene treatment hurler syndrom
scid gsdia hemophilia cystic fibrosi figur crsp current program focu ex
vivo gene disrupt compani anticip approach fastest clinic figur
crsp focus edit hsc ex vivo rapidli advanc program scd -thal
well edit t-cell ex vivo develop allogen car-t treat b-cell
malign crsp vivo applic target liver employ readili avail
deliveri technolog optim deliveri indic outsid liver
musculoskelet pulmonari ophthalmolog compani collabor vertex joint
ventur bayer casebia allow crsp access expertis hemophilia bayer cystic fibrosi
vertex collabor describ greater detail next section
figur progress applic
effort broaden rang indic compani pursu access industri lead
expertis enabl technolog specif therapeut area increas compani abil
invest platform enhanc program crispr form
collabor bayer vertex casebia joint ventur jv bayer own
two compani crsp receiv up-front payment crispr
therapeut initi public offer ipo commit jv fund bayer co-
develop crispr-bas medicin hemophilia scid well investig high-reward
diseas area ophthalmolog cardiolog figur addit casebia licens seattl
children gene-edit technolog use crispr edit gene regulatori t-cell
immun system provid casebia avenu treat autoimmun diseas crsp receiv
front billion potenti mileston vertex plu royalti research
collabor develop crispr base medicin
cystic
fibrosi
hemoglobinopathi term collabor hemoglobinopathi co-developed/co-
commerci crsp lead commerci parti figur
figur lead partnership bayer vertex
hemoglobinopathi
hemoglobin iron contain metalloprotein respons oxygen transport red blood cell
vertebr adult human common type hemoglobin tetram consist two
two -globin subunit
-thalassemia -thal aris varieti mutat gene encod -globin subunit
point mutat involv singl nucleotid substitut short insert delet
within gene and/or flank sequenc rarer instanc delet result either
complet loss -globin subunit product portion -globin subunit gene respons
gene regul two -globin subunit encod gene sever -thal
depend number mutat gene inherit one mutat -globin subunit gene
inherit -thal typic mild thalassemia mild -globin subunit gene
mutat -thal typic moder thalassemia intermedia sever thalassemia
major cooley anemia transfusion-depend -thalassemia sever case anemia
accompani bone marrow deform caus expand bone marrow enlarg spleen due
increas number ruptur red blood cell slow growth rate heart problem
thalassemia symptom caus mayo clinic transfusion-depend -thalassemia fatal
within first year life treat
respect nomenclatur beta plu mutat rang sever mild caus reduc
absent rate synthesi beta polypeptid chain mutat beta globin product
mutat allel complet absent -thal trait refer either genotyp
clinic mild condit result microcytosi mild anemia elev count
-thal homozygot compound heterozygot state result sever phenotyp sever
mutat state yield transfusion-depend thalassemia major
 genotyp involv milder beta mutat may produc thalassemia intermedia harri
root caus scd singl substitut sixth codon -globin gene lead
replac glutam acid residu valin scd autosom recess condit
requir parent pass copi mutant gene offspr upon deoxygen
hemoglobin hb polym form caus cell sickl damag membran figur
instanc sickl cell adher endotheli cell lead vaso-occlus instanc
hemolysi red blood cell occur leav free hb blood stream figur
sickl cell caus vascular injuri occlud small blood sometim larg vessel
process vaso-occlus initi sustain interact among sickl cell endotheli cell
constitu plasma vaso-occlus crisi lead hypoxia necrosi vital organ
respons sever complic scd complic includ acut episod
sever pain chest back abdomen extrem crise osteonecrosi nephropathi
hyposplen also caus vaso-occlus figur
sickl cell may also prone hemolysi break red blood cell increas
free plasma level hb well level liver enzym bilirubin former case higher
level free hb plasma decreas plasma concentr nitro oxid increas
plasma concentr ro reactiv oxygen speci lead pulmonari hypertens
leg ulcer priapism stroke latter instanc higher level bilirubin caus gallston
jaundic figur
genotyp childhood surviv death occur
year age quinn blood signific barrier treatment exist largest
proport patient popul typic african american commonli found either rural
econom disadvantag commun poor access physician
figur pathophysiolog sickl cell diseas
crsp util crispr increas product fetal hemoglobin hbf hereditari persist
fetal hemoglobin hpfh demonstr amelior effect morbid
patient -thal symptom patient scd includ asept necrosi stroke chest
syndrom crisi mening figur
hpfh aris either singl nucleotid substitut upstream promot region -globin
gene lead up-regul delet lead pan-cellular hpfh distribut
mutat elimin inhibitori sequenc down-regul hbf synthesi juxtapos remot
enhanc element adjac -globin gene wilber et al blood result known
benefit hpfh crsp tri increas hbf level mimic hpfh patient -thal scd
figur increas fetal hemoglobin allevi symptom beta-thalassemia
sickl cell diseas
wherea adult hemoglobin hba compris two two -globin subunit hbf
compris two two -globin subunit -globin subunit produc
develop fetu continu express high level birth -globin subunit
contrast predominantli express fetu typic express beyond six month
birth level -globin subunit elev fetu declin steadili
synthesi halt six month birth level -globin subunit rise significantli begin
three month birth continu sever month thereaft figur
figur birth hemoglobin switch fetal adult top panel -thal
order increas product hbf crsp crispr platform util modul
fetal adult hemoglobin shift character transit hbf hba synthesi gene
encod hemoglobin subunit arrang linearli human chromosom
switch transcript -globin subunit fetu -globin subunit adult
believ modul lcr locu control region chromatin open enhanc
element resid figur trans-act element influenc loop lcr enabl
facil transcript either -globin -globin gene loci known trans-act element includ
two repressor -globin gene express variant associ elev hbf
includ mutant -globin regulatori region partial delet globin locu delet long
strand dna includ hbd singl nucleotid variant erythroid
regulatori region keep data crsp focu effort edit
figur hemoglobin genom structur organ fetal adult switch model
 factor influenc transcript switch
figur diagram sever known hpfh variant top crsp approach
crsp demonstr creat specif gene variant use crispr guid rna grna
target specif dna locat within erythroid progenitor cell scd -thal patient well
healthi donor figur greater -globin mrna observ scd
-thal patient use grna see figur bi-allel edit increas
-globin mrna figur globin mrna ratio increas level
par asymptomat -thal individu sourc compani present perhap
significantli increas -globin mrna led concomit increas hbf protein scd patient
figur
figur crispr gene edit upregul hbf mrna protein patient
et al poster compani present
addit demonstr crispr util increas hbf mrna protein
erythroid cell scd increas hbf mrna level -thal patient crsp shown
edit cell retain potenti long-term repopul hematopoiet system use
immunocompromis mice differ grna use edit gene human cell
healthi donor edit cell introduc nsg mice week
post-engraft crsp demonstr presenc similar level human cell treat
untreat group confirm edit human cell retain engraft potenti figur
high rate edit demonstr variou cell type includ long-term hsc
figur long-term hsc differenti numer cell type
gmp cell high rate edit achiev
cell figur edit long-term hsc effect preval cell
type figur final edit cell maintain abil engraft differenti multi-lineag
potenti maintain edit figur
figur edit cell engraft mice human maintain human across
et al poster compani present
crsp submit clinic trial applic decemb support initi
phase i/ii trial -thal europ figur trial design determin safeti
efficaci adult transfus depend -thal patient compani plan submit
investig new drug ind applic support initi phase i/ii trial scd
current emerg treatment option scd -thal
nc develop lentiglobin gene therapi treatment scd -thal
lentiglobin lentivir vector insert function version gene patient
hsc ex vivo result engin hsc reintroduc patient lentiglobin
investig phase studi patient transfusion-depend
thalassemia tdt genotyp phase studi patient tdt
genotyp northstar phase i/ii studi patient tdt
genotyp phase studi patient tdt sever sickl cell diseas scd
phase studi patient scd figur
june initi result phase trial show three patient
treat studi age year achiev vivo vector copi number vcn
therapeut hemoglobin product good better patient achiev
transfus independ first northstar studi five patient genotyp
greater month follow-up remain free transfus median level
six month northstar g/dl across genotyp level gener sustain
second year follow-up
phase i/ii studi two three patient sever scd show total anti-
sickl hemoglobin level meaning clinic improv patient show rise
trajectori product first six month post-drug product infus on-going transfus
independ year report patient tdt three four
patient report normal near-norm total hemoglobin level
phase data studi two patient treat amend studi protocol
refin manufactur process show anti-sickl six nine month
respect exceed level seen previous studi
phase studi patient genotyp free transfus
median rang month two patient genotyp receiv
transfus year patient last studi visit month total hb level
g/dl level g/dl peripher vcn
endari l-glutamin emmau nc first newli approv agent scd sinc hydroxyurea figur
endari natur substanc decreas oxid stress red blood cell possibl
cell modest effect patient endari use either singl agent
combin therapi addit endari blood transfus pain medic
use treat scd
target hb polymer emerg viabl therapeut strategi treat scd benefit
hb polymer inhibitor includ decreas hemolysi increas hemoglobin tissu
oxygen decreas inflamm endotheli dysfunct decreas sickl cell pain
complic rivipansel glyc/pf nc crizanlizumab nv nc target p-
selectin figur glycoprotein involv cell adhes phase phase ii studi
respect patient scd nc develop
oral daili therapi phase trial act stabil hb oxy-conform
interfer oxygen releas figur deoxygen hb greater tendenc
polymer oxygen hb inhibit hb polymer stabil hb
sangamo nc util zinc-fing nucleas zfn disrupt gene
hsc zfn edit cell achiev long-term engraft gave rise
erythroid cell elev level hbf express chimer bone marrow cultur ex vivo
trial nameindicationphas i/ii northstar beta-thalassemia us transfusion-depend -thalassemia genotypesphas -thalassemia genotypesphas -thalassemia genotypesphas i/ii cell anemiaphas i/ii -thalassemia/sever sickl cell franc transfusion-depend -thalassemia sickl cell anemia crispr ag crsp
revenu project scd -thal model scd eu japan due
diseas preponder african american popul live african
american birth kaiser famili foundat kff org number birth race
incid scd patient popul center diseas control prevent
preval scd popul estim center diseas control prevent
assum peak penetr treatment price tag base spark
nc approv gene therapi luxturna voretigen neparvovec-rzyl cost
one-tim treatment forecast initi launch peak sale
reach billion scd figur
incid -thal eu estim respect
galenello et al orphanet journal diseas model launch -thal
price tag estim gener peak -thal sale
eu figur assum price europ discount
compar rel size european popul respect total
estim popul figur
druglead companytargetphaseendariemmau medic inc nicotinamid adenin dinucleotid nad /nadh approvedaltemiasancilio compani inc spci n/aiiipedroxaebel ebel inc fetal hemoglobiniiirivipanselpf inc selectinsiiivoxelotorglob blood inc group plc shpg hemoglobiniibrilintaastrazeneca plc azn adenosin diphosph receptoriicrizanlizumabnovarti ag inc phosphodiesteras pde inc guanyl cyclas sgc iisanguinateprolong llcstem cells/oth cell therapiesiisevuparinmodu hold abthrombin coagul factor iia coagul factor selectinsiicordingamida cell inc nf-kappa nuclear factor kappa-light-chain-enhanc activ cell cell shrna mir bluebird bio stem cells/oth cell therapiesiferriproxapotex inc ironilentiglobinbluebird bio inc nkt pharma inc phosphodiesteras pde llchemoglobinithalagenerr gene llcstem cells/oth cell therapiesiglucophagebristol-my squibb compani amp-activ protein kinas ampk investig initiatedaln-tmpalnylam inc transmembran proteas serin llchiston deacetylas hdac preclinicalarq inc inc limit edita fetal intellia/novarti inc fetal crsp fetal llcfetal blood inc inhibitor programregenaci llchiston deacetylas jolla pharmaceut compani llchiston deacetylas inc bivv stem cells/oth cell therapi fetal hemoglobinpreclinicaltrichosicerr gene llchiston deacetylas hdac preclin crispr ag crsp
note assum peak penetr scd -thal belief
crispr-engin hsc elev hbf captur total market
indic scd believ lentiglobin rivipansel crizanlizumab viabl
competitor market share note percentag incid preval -thal major
patient knowledg known therebi lower penetr estim -thal well
competit lentiglobin lower penetr still sinc intellia
mo pt use similar strategi crispr edit hsc ex vivo increas hbf
far earli declar winner model crsp captur half total
indic captur half
figur revenu model sickl cell diseas
figur revenu model beta-thalassemia
sickl cell epidemiologyafrican american birth per incid sickl cell cell new sickl cell patient epidemiologyu preval cell sickl cell patient patient cycl per year- price sale sickl cell beta thalassemia epidemiologytot us popul preval thalassemia beta thalassemia patient per price sale beta thalassemia ag crispr ag crsp
overview hemophilia
hemophilia recess x-link bleed disord affect individu
world-wide approxim one male birth x-link diseas result
gene mutat locat chromosom one two sex chromosom male
one chromosom one alter copi gene cell enough caus
hemophilia femal two chromosom mutat must present copi
gene caus diseas thu male affect x-link recess disord much
frequent femal nation genom research institut
sever differ type hemophilia howev common type hemophilia
classic hemophilia hemophilia christma diseas hemophilia caus lack
decreas clot factor viii hemophilia caus lack decreas clot factor
ix protein part complex clot cascad requir convert factor
fx activ factor xa fxa form fxa act along factor va fva mediat
convers prothrombin thrombin trigger activ fibrin fibrinogen initi
coagul blood clot format figur hemophilia hemophilia pathway
interrupt result inabl form normal clot
promin symptom patient hemophilia often bleed longer healthi
individu bleed occur intern joint muscl extern minor cut dental
procedur trauma bleed frequenc sever correl concentr fviii
plasma normal plasma level fviii rang
sever hemophilia symptom determin amount fviii blood mild hemophilia
character fviii blood mild hemophilia patient gener experi
bleed seriou injuri trauma surgeri mani case mild hemophilia diagnos
injuri surgeri tooth extract result prolong bleed first episod may occur
adulthood women mild hemophilia often experi menorrhagia heavi menstrual period
hemorrhag childbirth moder hemophilia character fviii
blood moder hemophilia patient tend bleed episod injuri sever
hemophilia character fviii blood sever hemophilia patient experi
bleed follow injuri may frequent spontan bleed episod often
joint muscl nation hemophilia foundat figur
figur hemophilia sever symptom
cdc hemophilia mutat project champ chbmp compil databas mutat factor
http //www cdc gov/ncbddd/hemophilia/champ html factor viii kb compris
exon figur protein synthes singl chain polypeptid amino acid signal
peptid remov endoplasm reticulum er
casebia strategi use crispr make cut dna remov defect factor viii gene
potenti use lnp deliv necessari rna mrna grna combin viral
deliveri correct fviii gene site-specif insert replac edit mutant gene
methodolog use compani address fviii mutat known caus
hemophilia severityfviii seriou injuri trauma episod follow injuri may frequent spontan bleed episod often joint muscl crispr ag crsp
thompson seminar thrombosi hemostasi
current emerg treatment option hemophilia
current therapi replac miss factor function downstream coagul process
current standard care hemophilia patient use inject recombin clot factor
function place mutant form respect nativ protein shire shpg nc hemophilia
franchis includ advat adynov well inhibitor therapi total billion
sale overal hemophilia market estim top billion hemophilia
drugcompanytargetphasecyklokapronpf inc plasminogenapprov gener competit feiba nfshire group plc shpg coagul factor viiiapprovednovosevennovo nordisk a/ nvo coagul factor coagul factor ixapprovedoctaplasoctapharma agn/aapprovedcoagyl center ibc generiumcoagul factor coagul factor ixapprov groupcoagul factor coagul factor ixblafitusiranalnylam inc thrombin coagul factor limit au coagul factor coagul factor ixii/iiimarzeptacog alfacatalyst bioscienc cbio coagul factor coagul factor ixii/iiiconcizumabnovo nordisk a/ nvo tissu factor pathway inhibitor coagul factor coagul factor inc tissu factor pathway inhibitor tfpi iifactor ix-ctpopko coagul factor xprogram holdcb-fxacatalyst bioscienc cbio thrombin coagul factor limit au coagul factor viii von willebrand factor vwf preclinicalfactor viiasavara inc coagul factor coagul factor ixpreclinicalfactor viii tregitop epivax epivax inc coagul factor viiipreclinicaloctapharma/glycotop blood coagul factor therapiesoctapharma agcoagul inc unknownpreclinicalsvfviiaamarna coagul factor viipreclinicaldruglead companytargetphaseadvateshir group plc shpg coagul factor xapprovedadynovateshir group plc shpg coagul factor xapprovedafstyla limit au coagul factor xapprovedalphanategrifol grf coagul factor viiiapprovedeloctatebioverativ inc bivv coagul factor xapprovedhemlibraroch hold ag rhhbi coagul factor coagul factor ixapprovedhumate-p limit au coagul factor coagul factor viii von willebrand factor vwf approvedkoate-dvigrifol grf coagul factor xapprovedkogen fsbayer ag bayri coagul factor xapprovedkovaltrybay ag bayri coagul factor xapprovednovoeightnovo nordisk a/ nvo coagul factor xapprovednuwiqoctapharma agcoagul factor xapprovedrefacto antihemophil factorpf inc coagul factor xapprovedxynthapf inc coagul factor xapprovedoctanateoctapharma agcoagul factor xapprov europevihumaoctapharma agcoagul factor xapprov europevoncento limit au coagul factor coagul factor viiiapprov europegreengen fgreen cross corpor factor viiiapprov /e octofactorintern center ibc generiumcoagul factor viiiapprov /e bay ag bayri coagul factor nordisk a/ nvo coagul factor xiiivaloctocogen roxaparvovecbiomarin pharmaceut inc coagul factor xiiibivv inc bivv coagul factor coagul factor inc coagul factor group plc shpg coagul factor inc coagul factor viiii/iibay ag bayri tissu factor pathway inhibitor tfpi coagul factor viiichina biolog product inc cbpo coagul factor xdevelop outsid pharmaceut inc coagul factor viiipreclinicalfactor ix/x bispecif antibodi shire shire group plc shpg coagul factor ix factor center ibc generiumcoagul factor viiipreclinicalhemophilia gene therapi bioverativ bioverativ inc inc n/apreclinicalsb-fviiisangamo inc coagul factor viiipreclinicalsernova cell pouch systemsernova corpor sva insulin receptorpreclinicalsvp/fviii gene therapi program spark/selecta inc coagul factor viiipreclin crispr ag crsp
note develop inhibitor seriou complic recombin clot factor treatment
hemophilia patient affect individu usual sever hemophilia
develop inhibitor fact inhibitor nation hemophilia foundat www hemophilia org
hemophilia defici factor ix risk much lower roughli order circumv
inhibitor develop mani patient sever hemophilia treat bypass agent includ
novoseven recombin fviia made novo nordisk nvo nc act independ fviii
via extrins system activ fx directli novoseven world-wide sale
estim billion
roch nc emicizumab hemlibra recent approv hemophilia
biomarin nc valoctocogen roxaparvovec vector gene therapi deliv
factor viii gene demonstr phase i/ii data sever hemophilia patient data present
decemb dose vg/kg median mean factor viii level week
vg/kg dose cohort consist within normal rang express
percentag normal factor activ blood week post infus median mean factor
viii level vg/kg cohort respect median annual bleed
factor viii use rate vg/kg zero week biomarin conduct two studi
global phase program valoctocogen roxaparvovec one vg/kg dose
one vg/kg dose
alnylam mo pt phase studi fitusiran first-in-class rnai therapeut
act target antithrombin
revenu project hemophilia
approxim hemophilia patient nation hemophilia foundat
hemophilia patient long-term inhibitor problem souci et al studi
prospect surveil inhibitor among person hemophilia us model
inhibitor popul hemophilia cdc non-inhibitor patient popul
model total hemophilia remain patient sever
hemophilia cdc would warrant treatment figur
model peak penetr eu japan base competit hemlibra
factor treatment fitusiran base penetr assumpt forecast initi launch
peak sale reach figur europ
japan figur assum price europ japan discount compar
 paramet defin hemophilia patient popul
europ japan base rel size european japanes popul
respect total estim popul respect
note valu npv crsp ownership casebia jv separ
royalti stream compani receiv casebia upon sale crispr-bas
therapeut hemophilia
figur revenu model hemophilia
hemophilia market model inhibitor patient hemophilia y/i share inhibitor patient treatment- hemophilia hemophilia y/i non-inhibitor sever share non-inhibitor patient treatment- patients- price y/i revenu ag crispr ag crsp
ctx allogen car-t cell malign
b-cell malign cll nhl mcl fl hodgkin express high level surfac
antigen attract target car-t therapi autolog obtain patient
therapi malign forefront whole new scientif paradigm
treatment b-cell malign august novarti nv nc receiv first ever fda
approv direct car-t cell therapi kymriah tisagenlecleucel show
overal remiss rate treat children young adult b-cell precursor acut lymphoblast
leukemia refractori second later relaps
follow remark success octob fda approv yescarta axicabtagen
ciloleucel nc direct car-t therapi treat adult patient certain type larg
b-cell lymphoma respond relaps least two kind
treatment multicent clinic trial evalu patient refractori relaps
larg b-cell lymphoma yescarta demonstr remiss rate patient respond
singl infus treatment addit ground-break clinic result sharehold
kite pharma enjoy signific market appreci kite acquir
gilead scienc august billion celgen celg mp recent agre
acquir juno billion
abil genet alter patient cell fight cancer novel therapeut
paradigm obstacl within new modal current limit widespread applic
take week prepar car-t cell expens process requir apheresi autolog
cell introduct car-t genet engin expans cell subsequ
reintroduct patient patient progress die car-t prepar
shorter manufactur process vital patient mani patient cell isol
blood sub-optimal due previou chemotherapi bone marrow transplant comorbid
manufactur perspect signific patient-to-pati variabl inher
prepar autolog car-t cell sourc variabl patient cell includ
contamin endotoxin mycoplasma replic compet retroviru lentiviru
genotox result level transgen integr level car cell
impur undesir cell type tumor burden potenc car-t cell wang et
al molecular therapi oncolyt complex autolog car-t manufactur
costli expens incur individu therapi pose commerci challeng although
celgen state context juno juno nc acquisit intend
reduc cost good juno car-t program
allogen car-t cell intend remedi issu describ inher
autolog car-t prepar figur allogen car-t product would avail off-the-
shelf immedi use without delay associ autolog car-t cell moreov
allogen cell taken healthi donor lymphocyt would degre consist
current possibl autolog
manufactur contrast higher cost manufactur process associ person
autolog treatment reli patient cell result streamlin manufactur
process consist cell base lower cost good sold realiz due simplif
manufactur process
figur advantag allogen car-t manufactur
given success autolog direct car-t treat refractori b-cell malign
overcom limit patient deriv cell describ creat off-the-shelf
allogen product garner signific scientif attent endogen t-cell receptor
tcr allogen cell lead graft versu host diseas gvhd recogn major
minor histocompat mhc antigen recipi therefor pose direct challeng
allogen therapi addit immun system patient major histocompat
complex class mhc may recogn allogen donor deriv cell foreign rapidli reject
varieti gene edit techniqu includ zinc finger zf transcript activator-lik
effector nucleas talen test edit tcr mhc loci cell
sangamo bioscienc nc collabor san raffael demonstr zinc finger
edit remov tcr -gene human cell lymphocyt enabl seven mice
surviv four week preclin studi without develop lethal gvhd contrast six mice receiv
unmanipul cell four five mice receiv tcr transfer lymphocyt die lethal gvhd
within two week provasi et al separ studi sangamo academ
collabor fred hutchinson cancer research center md anderson mit show
gene edit use zinc finger nucleas select elimin hla express
cell enabl cell evad lysi hla-restrict cytotox t-cell clone torikai et al blood
use off-the-shelf car-t edit use talen multiplex target cell
receptor alpha constant chain locu trac gene locu cellecti cll
nc investig great ormond street hospit univers colleg london institut child
induc cytogenet molecular remiss one-year old girl relaps
bone-marrow transplant qasim et al first clinic applic talen engin univers
cell separ studi cellecti demonstr multiplex edit
trac loci produc allogen direct car-t cell destroy tumor
even presenc alemtuzumab campath sni nc potent chemotherapeut agent
rna guid nucleas crispr superior technolog compar zf
talen rel eas engin scalabl afford crispr make gene
edit technolog attract candid wide-spread commerci use edit gene key featur
crispr multipl guid sequenc encod singl crispr array enabl
simultan edit sever site within mammalian genom multiplex use
simultan knockout tcr mhc cell use lentivir vector incorpor
edit strategi clinic progress
crispr demonstr multiplex edit tcr mhc figur
prevent gvhd compani achiev knock-out effici tcr prevent host immun
clearanc compani achiev greater cell resist host immun clearanc
mhc knock-out singl electropor compani shown cell
tcr- mhc i- doubl knock-out concomit insert tcr- cell secret
interferon upon antigen engag cell strong interferon secret observ
cell compar control tcr- antigen control
perhap significantli preclin studi crispr allogen car-t yield
promis result compani initi lead allogen car-t candid consist
insert combin doubl knock-out tcr microglobulin figur
 essenti subunit mhc vitro experi compar cell lysi treat cell
either autolog lentivir car-t allogen car-t show allogen
car-t effect autolog counterpart vivo experi aggress
dissemin raji lymphoma model show allogen car-t prolong surviv
crispr pursu regulatori strategi seek approv patient
popul ident autolog car-t therapi gain approv kymriah
novarti nc evalu children young adult b-cell precursor acut lymphoblast
leukemia refractori second later relaps yescarta nc evalu adult
patient certain type larg b-cell lymphoma dlbcl respond
relaps least two kind treatment compani conduct futur clinic trial
inclus dlbcl patient ind file expect
august novarti nv nc receiv first ever fda approv direct car-t
cell therapi kymriah tisagenlecleucel show overal remiss rate treat children
young adult b-cell precursor acut lymphoblast leukemia refractori
second later relaps
octob fda approv yescarta axicabtagen ciloleucel nc direct
car-t therapi treat adult patient certain type aggress b-cell lymphoma
respond relaps least two kind treatment multicent clinic
trial evalu patient refractori relaps larg b-cell lymphoma yescarta
demonstr remiss rate patient respond singl infus treatment
march juno juno nc discontinu rocket trial adult
death rate studi five patient receiv death rate
compar car-t trial treat adult late-stag five death
cerebr edema sever brain swell side effect surfac experiment
car-t program compani recent pivot focu program prior
intend acquisit celgen
bellicum blcm nc develop rimiducid improv outcom patient
aml undergo haploident partial match transplant core compani
technolog safeti switch induc rimiducid kill transplant hsc patient
receiv benefit cell fight infect support engraft prevent diseas
relaps gvhd occur caspacid safeti switch activ kill toxic cell
june bellicum report data pediatr patient within on-going phase i/ii
trial show rapid immun recoveri low incid transplant-rel mortal reduct
viral infect low rate gvhd manag either standard treatment
rimiducid data suggest rimiducid could improv outcom haploident stem cell transplant
provid life-sav transplant option mani patient could benefit lack match
donor addit data trial cohort pediatr patient acut leukemia
lack match donor show rapid immun reconstitut low rate relaps suggest
may offer benefit combin hsct patient acut leukemia
cellecti cll nc develop off-the-shelf car-t candid servier
nc second cll therapi consist lentiviral-transduc car-t cell express
safeti switch intend allow target elimin
cell rituximab lentivir transduc car-t cell edit use talen
disrupt trac gene
data two phase trial relaps refractori adult patient
pediatr patient present open-label dose-escal phase studi
design evalu safeti toler anti-leukem activ adult
relapsed/refractori patient show five seven patient treat achiev molecular
remiss defin neg minim residu diseas mrd day post
administr one grade cutan acut gvhd occur sever neurotox
observ cytokin releas syndrom mild manag except one patient treat
first dose level develop grade neutropen sepsi lead
death day
open-label pall phase studi design evalu safeti abil induc
molecular remiss defin mrd neg day enabl allogen stem cell
transplant pediatr patient high-risk relapsed/refractori data pall phase
studi show five children achiev mrd neg enabl proceed allogen
stem cell transplant one grade cutan acut gvhd occur sever neurotox
observ cytokin releas syndrom mild major case manag
cellecti phase studi target evalu immunotherapi
patient acut myeloid leukemia aml blastic plasmacytoid dendrit cell neoplasm
bpdcn due death bpdcn studi first patient treat trial
place clinic hold patient death attribut grade cytokin releas syndrom
grade lung infect contribut fda decis place studi
clinic hold aml patient treat experienc similar milder complic
celyad cyad nc develop off-the-shelf car-t therapi celyad allogen technolog
current preclin stage expect enter clinic year precis bioscienc
develop off-the-shelf car-t therapi use synthet home endonucleas technolog
note edita mo pt partner juno focus engin car-t
target intracellular antigen hpv antigen intracellular antigen recogn tcr
oppos cell-surfac express antigen recogn
revenu project dlbcl
incid estim figur pediatr
patient popul long-term surviv pediatr popul model
pediatr patient relaps refractori incid patient popul compris
adult estim
b-cell malign consid
incid dlbcl estim dcbcl review cancer
medicin list essenti medicin union intern cancer control
patient popul treat chop-lik regimen plu rituximab gisselbrecht et al
journal clinic oncolog estim address patient popul add
refractori relaps refractori dlbcl patient togeth refractori popul estim
refractori treatment patient also fail respond salvag
chemotherapi relaps refractori patient popul estim five-year preval
dlbcl number treat dlbcl patient minu refractori patient fail respond
salvag treatment year multipli five five-year rate
estim five-year preval dlbcl patient popul undergo treatment
patient fail respond treatment rovira et al ann hemat figur
forecast initi launch peak sale reach
figur europ japan forecast initi launch
peak sale dlbcl reach billion figur billion
europ japan figur assum price europ japan
discount compar paramet defin dlbcl
patient popul europ japan base rel size
european japanes popul respect total estim popul
note assum peak penetr dlbcl
belief allogen car-t modifi use crispr captur total market
indic sinc intellia develop similar allogen car-t product
dlbcl far earli declar winner model crsp captur half
total allogen car-t penetr indic captur half
figur market model
figur market model dlbcl
pediatr patient indic us relaps pediatr patient patient adult patient indic us origin b-cell relaps adult patient patient patient therapi price sale dlblc incid dlbcl treat chop-lik regimen plu treat dlbcl refratori primari chemorefractori fail respond salvag dlbcl five-year preval relaps fail respond salvag refractori dlbcl total address patient market dlbcl patient treat price incresa sale us mm crispr ag crispr ag crsp
crsp licens foundat patent estat human therapeut use
compani scientif founder dr emmanuel charpenti director max planck institut infect
biolog patent estat part charpentier/berkeley ip estat uc
licens crsp carib bioscienc intellia figur ip direct
broadli genom edit includ mani differ applic technolog
crsp file addit ip applic continu support compani mission
bring transform gene-bas medicin patient seriou diseas uc patent estat
subject disput form interfer proceed broad institut main
argument uc broad summar
uc believ overarch impact jinek jinek et al scienc programm
dual-rna guid dna endonucleas adapt bacteri immun uc
highlight tremend scientif achiev dr doudna dr charpenti colleagu
identifi necessari suffici compon crispr system uc argu
techniqu use broad transfer crispr eukaryot cell codon optim
promot vector microinject use convent cite broad scientist expert opinion
uc argu indic suggest scientist believ crispr would work
eukaryot cell point jinek special sauc
group describ move eukaryot knowledg necessari
suffici compon essenti argu uc expound singl
molecul invent compon jinek dual-tracrrna crrna engin
singl rna chimera doudna team
uc describ known time whether uniqu coval
attach separ rna would maintain function provid scientif evid risk
alter natur system chang orient rna prevent protein
bind nucleic acid significantli applic single-guid technolog limit
broad believ obviou make crispr work eukaryot cell broad
argument attempt dampen impact jinek effort counter uc content
jinek made move crispr prokaryot eukaryot obviou knowledg
provid jinek necessari get crispr work eukaryot
broad argu known time whether prokaryot crispr system
could transfer eukaryot concern exist prior cong cong et al zhang
multiplex genom engin use crispr/ca system scienc
whether could actual done broad team contend effect
chromatin structur dna wind eukaryot phenomenon found prokaryot
necessari compon identifi prior jinek guidanc prior cong
transfer crispr eukaryot cell broad argu despit uc
knowledg motiv skill could get crispr work eukaryot cell
broad legal team point antithesi someth obviou cong
broad argu could person ordinari skill art use crispr eukaryot
process februari patent trial appeal board ptab
rule interfer fact behalf broad figur respons juli
gene edit consortium crsp carib bioscienc er genom
announc submiss appel brief seek revers patent board interference-
in-fact decis brief submit regent univers california univers
vienna dr emmanuel charpenti collect uc feder circuit case
one rung suprem court appeal seek revers februari patent trial
appeal board ptab decis interference-in-fact ptab conclud broad
provid suffici evid show patent claim limit system
eukaryot environ drawn invent uc claim
uc appel brief assert ptab fail properli appli control suprem court
feder circuit preced take consider evid multipl group use
teach charpentier-doudna team appli eukaryot cell
new evid introduc appeal process appeal court act
independ review fact case rather court appeal role sole
determin whether ptab commit error law lack substanti evid reach
decis
figur global patent coverag
process eu march epo announc intend grant crsp
patent cover compani single-guid gene edit system use non-
cellular cellular set includ human mammalian cell well use
therapi treat patient epo decis grant patent single-guid crispr/
crispr invent believ clearli develop dr jennif doudna
emmanuel charpenti colleagu uc berkeley follow two award patent uk
march februari respect figur
mean crispr
highlight fact multipl compani involv develop recombin
protein monoclon antibodi rnai-bas molecul despit issuanc domin ip
one parti cohen boyer case recombin protein queen cabilli
boss case monoclon antibodi tuschl kreutzer/limm case rnai
believ except rule competitor complet exclud abil
practic particular form technolog ultim believ issu may simpli resolv
via nomin licens fee broader cross-licens agreement amongst variou parti
litig crispr patent pool believ current uncertainti
hangov effect valuat compani
jmp secur llc compani report
statement product research develop revenu relat revenuetot good expens research oper incom expens interest expenseloss equiti method exstinguish convert loanoth expens incom net incom incom incom incom currenc translat net loss net loss attribut common shareholdersnet incom attribut non-control loss attribut common ep common dilut ep common basic share share crsp crispr ag crispr ag crsp
decad biotechnolog industri view disrupt technolog come
along offer signific upsid potenti investor foresight see patienc
ride long term investor could purchas share number
publicli trade first-gener biotech compani genentech
busi exploit recombin dna technolog retrospect low valuat
compani abgenix part medarex part bristol-my
squibb nc revolution antibodi space eventu sold sizabl sum
alnylam came along complet revolutionari approach develop
novel therapeut har endogen cellular mechan known rna interfer
rnai view success translat laboratori scienc power
therapeut platform part alnylam modern day paradigm drug discoveri
develop one fulli expect crispr medicin emul
signific parallel recognit power rnai develop
new modal human therapeut well applic agricultur recent
surg interest crispr stand cluster regularli interspac short palindrom
repeat term also use refer technolog portion refer
bacteri enzym use perform actual gene edit like rna interfer
phenomenon crispr first observ lower organ case rnai plant
specif tulip case crispr system evolv kind bacteri immun system
use fight invad pathogen thu like antibodi protein rna interfer crispr exist
natur
research perform genet sequenc bacteria discov sequenc
bacteri genom overlap found phage type organ infect bacteria
sequenc conserv bacteri progeni use futur infect
sequenc match made bacteri phage dna enzym also refer
nucleas recruit cut disabl phage dna technolog also employ
rel mundan way product yogurt ensur bacteria use produc
yogurt infect phage observ made danisco divis dupont
dwdp nc appli genom edit gener human genom edit particular
power crispr system induc double-strand break dna via use
simpl rna guid strand speed low cost effici process great
becom de facto standard academia perform knockout experi
mani kind cell includ mammalian fulli anticip commerci develop crispr
technolog take advantag improv inevit brought
grow number research work area
power modifi gene mammalian cell vividli demonstr
public chines research natur magazin describ birth two
monkey pre-determin mutat ppar- gene nearli year prior
research publish paper natur demonstr knockdown apolipoprotein apob
gene primat model use rnai
much public touch frenzi research rnai space
primat public produc type reaction crispr space public also
ignit signific controversi regard potenti engin human embryo prospect
design babi unsurprisingli receiv breathless coverag lay media
germlin gene edit certainli feasibl compani particip gene edit space
includ util crispr talen cellecti cll nc zfp sangamo
nc declar publicli engag germlin gene edit
specif limit research somat cell addit intern confer held
nation academi scienc decemb repres industri academia
regulatori bodi uk china discuss ground rule everyon
agre oper describ detail crispr white paper
purpos explan help separ hype realiti sector strong
fundament crispr technolog hold promis treat mani genet diseas way
simpli possibl technolog approach view addit knock
disease-caus gene crispr hold potenti replac repair approach
diseas gene perhap gene excis replac correctli function version
gene anoth futur applic crispr technolog could involv catalyt dead
element serv recruit tool protein machineri necessari activ
transcript factor turn activ gene inappropri silenc diseas
exampl gene silenc nearli one-half cancer reactiv use
catalyt dead anoth orthologu could repres novel way treat cancer given
much ground conquer genet diseas view long
time come ever select trait children catalogu therefor
believ investor confid scienc manag team crispr
therapeut well long-term vision may well reward
known revolutionari genome-edit tool deriv natur occur bacteri
process call crispr shorten cluster regularli interspac short palindrom
repeat array repetit sequenc direct repeat interspac short
stretch non-repetit sequenc spacer specif crispr defens mechan
evolv bacteria protect virus crispr loci bacteria express small rna
sequenc match uniqu nucleotid sequenc genom invad virus
complementari sequenc viral genom bind bacteri crispr rna also bring
nucleas enzym call crispr-associ enzym ca thu bacteria
infect viru render harmless cleav small piec ca enzym
adapt crispr gene edit
stem work led dr jennif doudna dr emmanuel charpenti respect
team separ team dr feng zhang georg church broad institut
harvard respect exploit natur bacteri immun mechan crispr gene-
edit system becom new arsen field biolog genom engin
crispr/ca system compos ca endonucleas guid rna grna grna
compris two rna compon crispr short rna sequenc confer sequenc
specif therebi help lead ca enzym particular locat transactiv crispr
rna requir form complex ca enzym enabl activ prototyp
enzym use gene edit come streptococcu pyogen bacteria although
ca enzym exist edit enzym discov real time
importantli crispr/ca system also requir sequenc known pam protospac adjac
motif protein bind although pam site found frequent genom
often everi requir restrict target rang howev pam
depend also increas specif new technolog current
develop may reduc target rang littl collect express
compon togeth gener site-specif double-strand break dsb enabl modif
endogen site eukaryot cell rapidli eas unlik edit tool avail
endogen repair mechan nhej hdr
well-establish principl biolog double-strand break dna promot gene edit
dsb serv substrat cell natur repair machineri work via two differ mode
non-homolog end join nhej homology-direct repair hdr mechan
facilit engin target mutat repair endogen mutat introduct
transgen dna element dsb gener crispr preferenti repair nhej
resolv lower frequenc hdr nhej rapid error-pron process work glu
two cut end togeth work rapidli
specif break nhej repair caus indel insert delet mutat
occur nhej repair mechan har introduc insert delet
mammalian cell second type repair slower accur cell machineri
correct damag sequenc copi nearbi dna sequenc hdr offer mean
specif modifi endogen sequenc via replac point mutat insert knock-in
allel short sequenc dna introduc hdr gener activ divid cell
effici vari cell type state genom locu templat
context gene manipul
classic gene therapi copi gene introduc without remov replac exist dna
hope deliveri healthi allel patient genom perform expect function
convers rna interfer work target specif messeng rna mrna molecul
destruct therebi chang sequenc dna transcrib caus silenc
gene product contemporari edit techniqu hand permit actual alter dna
specif target sequenc deliveri gene therapi gene edit techniqu reli either
vivo ex vivo mode main edit techniqu involv programm nucleas
guid particular nuclear sequenc cleav creat dsb dna
nucleas use molecular scissor cut remov introduc new genet materi
three main gene edit tool current use includ zfn zinc-fing nucleas
crispr versu gene-edit technolog
although gene modif tool avail offer advantag pace eas
afford crispr/ca system make appeal technolog view
although crispr introduc year ago recent find indic crispr paper
far outnumb either zfn talen
figur crispr public outstrip gene-edit technolog
crispr/ca system rapid enabl simultan effici target multipl site
implement inexpens offer versatil becom go-to
system research zfn talen recogn longer dna sequenc theoret
better specif crispr effici zfn talen also requir
creation custom-design zfn talen protein time wherea creat grna
rel straightforward carri high likelihood work note
although system offer great potenti without limit compar zfn
talen character higher risk off-target mutat howev group
particular georg church taken step address one mean ensur specif
via lower dosag crispr/ca convert nickas maintain
effici on-target cleavag implement system
greater appreci differ nucleas deeper understand
technolog compani present util tool pleas refer deep dive entitl
trend develop dna edit technolog
dr samarth kulkarni ceo dr samarth kulkarni signific expertis strategi oper
biotech wide rang relat cutting-edg therapeut technolog previous
mckinsey compani lead role medic
product practic mckinsey dr kulkarni co-l biotech practic serv number
biotechnolog compani topic rang strategi oper addit led initi
area person medicin immunotherapi co-author sever public
dr kulkarni receiv ph bioengin nanotechnolog univers
washington indian institut nolog univers
washington conduct research deliveri biolog drug field molecular
diagnost publish numer lead journal
dr rodger novak co-found presid dr rodger novak co-found crispr therapeut
togeth dr emmanuel charpenti shaun foy experienc pharmaceut
biotechnolog execut former univers professor vienna biocent austria bring
combin scientif experi gain academ career proven track record
success translat technolog pharmaceut product
recent posit dr novak global head anti-infect research develop
sanofi respons small molecul biolog includ earli drug discoveri
clinic develop founder serv chief
oper offic almost six year start pharmaceut career sandoz novarti
appoint deputi head antibiot research institut
dr novak receiv philipp univers marburg germani foreign
medic licens postdoctor fellow rockefel univers st
jude children research hospit skirbal institut nyu medic center academ
articl
natur natur
medicin molecular cell dr novak co-inventor five patent
michael tomsicek cfo michael tomsicek signific experi corpor financ oper
manag system corpor collabor
therapeut serv chief offic cfo publicly-trad provid
medic devic cfo cubist pharmaceut held seri role
increas respons lead financ investor relat strateg sourc prior cubist mr
tomsicek spent nearli eight year gener electr healthcar ultim cfo ultrasound
mr tomsicek hold bachelor scienc engin master busi administr
univers wisconsin
dr toni ho head research develop dr toni ho highli accomplish leader
experi across phase includ discoveri earli late-stag clinic
develop regulatori throughout nearli career previous senior vice
presid head oncolog integr innov astrazeneca tenur
astrazeneca oversaw develop commerci two key drug lynparza
first-in-class parp inhibitor ovarian cancer imfinzi astrazeneca first immuno-
oncolog drug bladder cancer drug led program file regulatori defens
payer access commerci launch initi phase develop across multipl tumor type
prior join astrazeneca dr ho neurolog ophthalmolog clinic section head
merck research laboratori merck co inc led multipl develop program includ
approv maxalt pediatr migrain zioptan glaucoma prior join merck
co-found chief scientif offic neuronyx inc regen medicin compani
dr ho complet electr engin univers california lo angel
receiv john hopkin univers school medicin internship intern
medicin massachusett gener hospit complet resid neurophysiolog
fellowship depart neurolog john hopkin hospit assist professor
john hopkin hospit area neuropathi neuromuscular diseas publish
wide sever field paper co-inventor seven patent current adjunct
associ professor neurolog univers pennsylvania assist professor neurolog
dr tyler dylan-hyd chief legal offic dr tyler dylan-hyd two decad
experi law firm in-hous privately-held public compani develop gene-
base therapeut technolog
morrison foerster llp special develop defens global ip
portfolio licens corpor transact in-hous gener counsel help lead collater
therapeut ipo later acquir schere ag bayer
healthcar pharmaceut innercool therapi advanc fda clearanc
acquir philip healthcar develop portfolio compani
acquir other current partnership
receiv sc cell molecular development biolog mcgill univers montreal
canada ph biolog univers california san diego
univers california berkley boalt school law co-inventor sever patent
applic co-author number scientif public
jim kasing gener counsel secretari board director jim kasing nearli
year experi advis counsel privat public compani biotechnolog
technolog sector prior join compani gener counsel secretari
cambridge-bas biotechnolog compani among thing
help lead two equiti financ rais nearli billion sever collabor includ az
merck vertex gener counsel plumchoic inc provid technic
support servic fortun compani go in-hous mr kasing partner
busi practic group global law firm goodwin procter llp repres life
scienc technolog high-growth compani stage life cycl format
obtain seed growth financ initi public offer merger sale start legal
career associ testa hurwitz thibeault
receiv boston colleg law school graduat cum laud wheaton
dr subramanian svp strateg develop oper dr subramanian
extens experi strateg plan portfolio program manag across early- late-
stage develop oncolog therapeut area recent posit dr
subramanian vice presid global head strateg develop program manag
novarti pharmaceut oncolog respons program portfolio
manag strateg plan resourc alloc manag budget also
respons integr gsk oncolog novarti includ full align portfolio
organ peopl program manag millennium senior
consult accentur
dr subramanian receiv ph physic chemistri cornel univers post-
doctor fellow duke univers medic center
dr jon terrett head immuno-oncolog research translat dr jon terrett
extens track record discov progress immuno-oncolog drug candid clinic
prior join vice presid oncolog discoveri cytomx
 -base biotechnolog compani focus develop drug treat differ type cancer
addit held variou leadership role biopharma includ serv chief scientif
offic oxford biotherapeut director variou biotechnolog compani includ
medarex celltech oxford glycosci
dr terrett receiv genet univers sheffield doctor genet
univers nottingham
megan wherri menner svp human resourc megan wherri menner extens hr
experi pharmaceut biotech life scienc industri previous merck
kgaa eight year recent vice presid head hr global merck
millipor life scienc busi role respons hr strategi busi partnership
hr function align life scienc busi includ peopl organ
integr sigma-aldrich acquisit also merck kgaa serv vice-president head hr
respons hr team member countri well vice-president
head hr emd serono led hr function pharma busi
ms menner spent five year novarti period rapid growth recent
serv head cultur develop entir research organ global
held sever senior hr busi partner role uk also work leadership
develop hr busi partnership bristol-my squibb earlier career
acquisit softwar start-up compani outgrowth mit sloan busi school
acquir
ms menner earn bachelor degre psycholog econom master degre
human resourc organiz behavior cornel univers
